IP Library Granted Patent US 9,707,238
Granted Patent B2
US 9,707,238 · App. 14/822,646 · Granted Jul 18, 2017

Oil-in-water method for making polymeric implants containing a hypotensive lipid

Inventors: James Chang (Newport Beach, CA); Patrick Hughes (Aliso Viejo, CA); Chin-Ming Chang (Tustin, CA)
Assignee: Allergan, Inc.
A61K31/5575A61K9/0048A61K9/0051A61K9/107A61K9/1075A61K9/146A61K9/1647A61K9/1694A61K31/165A61K47/34B01J13/04B01J13/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,707,238
App. No.
14/822,646
Granted
Jul 18, 2017
Kind
B2
Abstract

Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.

Claims (12)

1. A population of microparticles comprising a polymeric component encapsulating travoprost in the form of oil-in-water emulsified microparticles.

2. The population of claim 1 , wherein the polymeric component comprises a poly(lactide-co-glycolide) copolymer.

3. The population of claim 1 which is terminally sterilized.

4. The population of claim 3 , wherein at least 80% of the travoprost remains stable after the sterilization.

5. The population of claim 1 having a mean particle diameter from about 30 μm to about 50 μm.

6. The population of claim 1 , wherein the maximum particle diameter is less than about 200 μm.

7. The population of claim 1 , wherein the microparticles have a release rate of the travoprost of about 0.7% per day in vitro.

8. The population of claim 1 , wherein the travoprost comprises about 10% wt/wt of the microparticles.

9. The population of claim 1 , wherein the travoprost comprises about 5% wt/wt of the microparticles.

10. A method of treating an ocular condition in an eye of a patient, comprising the step of placing the population of claim 1 in an eye of a patient.

11. The method of claim 10 which is effective to treat glaucoma.

12. The method of claim 10 which is effective to decrease intraocular pressure.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2015
From: CHANG, JAMES; HUGHES, PATRICK M.; CHANG, CHIN-MING
To: ALLERGAN, INC.
Reel/Frame 036302/0033 →
Continuity (6)
Continuation 14228020 · Mar 27, 2014
Division 11371118 · Mar 8, 2006
Continuation In Part 11368845 · Mar 6, 2006
Continuation 11303462 · Dec 15, 2005
Continuation In Part 10837260 · Apr 30, 2004
Related Publication 20160015718A1 · Jan 21, 2016